GlassScriptPhysician profile
Kevin M Woods
NPI 1568569549
$6,345.11
in general payments reported to CMS, 2019-2025
29 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,421 · 2020: $294 · 2021: $368 · 2022: $710 · 2023: $1,273 · 2024: $1,188 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,551.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,638.80 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $610.05 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $479.92 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $470.02 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $387.29 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $316.80 | 2019-2025 | Farxiga, Wainua |
| Amgen INC. | $310.51 | 2019-2025 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $275.33 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $248.76 | 2021-2023 | Arcalyst |
| Aop Health US, LLC | $195.65 | 2025 | Rapiblyk |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $170.10 | 2019-2022 | |
| Chiesi USA, INC. | $146.67 | 2020-2023 | Kengreal, Cleviprex |
| Alnylam Pharmaceuticals INC. | $138.89 | 2023-2025 | Onpattro |
| Lexicon Pharmaceuticals, INC. | $133.98 | 2023-2024 | Inpefa |
| Arineta, INC | $112.34 | 2024 | Spotlight |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $101.13 | 2020-2022 | |
| Gilead Sciences, INC. | $76.27 | 2019 | |
| Merck Sharp & Dohme LLC | $69.36 | 2022-2024 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $60.04 | 2019 | |
| Scpharmaceuticals INC. | $52.98 | 2025 | |
| Cleerly, INC. | $50.33 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Astellas Pharma US INC | $49.49 | 2019 | |
| Bard Peripheral Vascular, INC. | $45.90 | 2024 | Venclose Maven Catheter |
| Cvrx, INC. | $45.77 | 2025 | Barostim Neo System |
| Bridgebio Pharma, INC. | $41.79 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $41.57 | 2019 | |
| Boston Scientific Corporation | $28.55 | 2019 | |
| Portola Pharmaceuticals, LLC | $26.00 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.